Clinical outcomes of phenotype-guided treatment in group D carbapenemase-producing Enterobacterales bacteremia
Open Access
- 1 July 2025
- journal article
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (7) , e0027325
Abstract
International guidance recommends ceftazidime-avibactam for OXA-48-type carbapenemase-producing Enterobacterales (OXA-48-CPE) infections. However, OXA-48-CPE lacking extended spectrum and AmpC β-lactamases may remain susceptible to third-generation cephalosporins (3GC), potentially allowing treatment without avibactam. OXA-23 also has variable hydrolytic activity against 3GC. This study reviewed the outcomes of OXA-CPE bloodstream infections treated based on phenotypic susceptibility testing. A retrospective review of OXA-48-CPE and OXA-23-CPE bloodstream infections was conducted from February 2022 to July 2024. Data on antimicrobial susceptibility, patient background, infection source, treatments, and outcomes were analyzed. Whole-genome sequencing (WGS) determined the presence of β-lactamase genes in available isolates. Ten bloodstream infection episodes occurred in nine patients (eight OXA-48-like Escherichia coli [ n = 4], Klebsiella pneumoniae [ n = 4], and one OXA-23-CPE Proteus mirabilis ), with a urinary source in 44.4% ( n = 4). Of the isolates, 5/9 (55.5%) were 3GC-susceptible. WGS did not identify any extended-spectrum β-lactamases in these isolates. Three 3GC-susceptible cases (two OXA-48 and one OXA-23) were successfully treated with ceftriaxone. Among the 3GC-resistant cases, two were treated with ceftazidime-avibactam, and two with high-dose meropenem alone or in combination with aztreonam. One recurrence was observed in a case treated with ceftazidime-avibactam. Mortality was low, with one death reported in a patient treated with ceftazidime-avibactam. In this small study, 55.5% of OXA-48-CPE and OXA-23-CPE isolates retained 3GC susceptibility. When used for therapy, 3GC and non-β-lactam antibiotics demonstrated clinical efficacy where antibiotic susceptibility was demonstrated. IMPORTANCE: The Infectious Diseases Society of America guidance document recommends the use of ceftazidime-avibactam for the treatment of OXA-48-type carbapenemase-producing Enterobacterales (OXA-48-CPE). However, this antibiotic is expensive and not always available in some settings. The clinical outcomes of OXA-48-CPE and OXA-23-CPE bloodstream infections when treated with third-generation cephalosporin (3GC) remain unclear. Among 10 episodes in nine patients, we found that five isolates (55.5%) were 3GC-susceptible, with three cases successfully treated with ceftriaxone. Whole-genome sequencing demonstrated the absence of extended-spectrum β-lactamases in the 3GC-susceptible isolates, which aligns with phenotypic 3GC susceptibility. Mortality was low (1/9). Many OXA-48-CPE and OXA-23-CPE infections retain 3GC susceptibility, raising the possibility that these agents may be viable alternatives to ceftazidime-avibactam in select cases.Keywords
This publication has 16 references indexed in Scilit:
- Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative InfectionsClinical Infectious Diseases, 2024
- Proteus mirabilis – analysis of a concealed source of carbapenemases and development of a diagnostic algorithm for detectionClinical Microbiology and Infection, 2023
- Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus ComplexClinical Infectious Diseases, 2023
- Healthcare-associated multispecies outbreaks of OXA-48–positive carbapenemase-producing Enterobacteriaceae in a Singapore tertiary-care hospitalInfection Control & Hospital Epidemiology, 2022
- A single Proteus mirabilis lineage from human and animal sources: a hidden reservoir of OXA-23 or OXA-58 carbapenemases in EnterobacteralesScientific Reports, 2020
- The difficulties of identifying and treating Enterobacterales with OXA-48-like carbapenemasesClinical Microbiology and Infection, 2020
- Infections by OXA-48-like-producing Klebsiella pneumoniae non-co-producing extended-spectrum beta-lactamase: Can they be successfully treated with cephalosporins?Journal of Global Antimicrobial Resistance, 2019
- Evaluation of an in-house developed multiplex real-time PCR for the detection of IMP, OXA-23, GES carbapenemases and the transmissible colistin-resistant mcr gene on the BD MAX™ open systemDiagnostic Microbiology and Infectious Disease, 2018
- Antimicrobial treatment and outcomes of critically ill patients with OXA-48like carbapenemase-producing Enterobacteriaceae infectionsDiagnostic Microbiology and Infectious Disease, 2015
- First report of emergence of OXA-48 carbapenemase-producing Enterobacteriaceae in Singapore: Proactive or reactive infection control strategy?American Journal of Infection Control, 2014